ZLAB Earnings Prediction
The chart below shows how ZLAB performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ZLAB sees a -5.13% change in stock price 10 days leading up to the earnings, and a -2.08% change 10 days following the report. On the earnings day itself, the stock moves by +0.18%. This data can give you a slight idea of what to expect for the next quarter's release.
ZLAB Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
109.07M
65.68%
6.65%
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
ZLAB Earnings Analysis
Zai Lab Ltd Corporation (ZLAB.O) Earnings Conference Call
Positive
Revenue Surge in 2024: Total revenue for 2024 grew 50% year-on-year with an exceptional 66% growth in the fourth quarter.
Immunology Launch Success: VYVGART generated $93.6 million in sales in 2024, marking it as one of the best immunology launches in China.
Product Launch Advancements: Substantial progress in advancing regional assets with several new product launches, including VYVGART Hytrulo, AUGTYRO, and XACDURO.
Promising Product Launches Ahead: Positive data readouts for KarXT, Tumor Treating Fields, and TIVDAK, paving the way for multiple launches next year.
Promising Response Rate: ZL-1310 showed a 74% overall response rate in preliminary data, with plans for a pivotal trial this year.
Operational Loss Improvement: Loss from operations improved year-over-year by 45% in Q4 and 23% for the full year, indicating better financial health.
Strong Cash Reserves: Robust cash position of $879.7 million to support growth initiatives.
2025 Revenue Guidance: Total revenue guidance for 2025 is projected to be between $560 million to $590 million, reflecting strong growth expectations.
Negative
Operational Loss Reduction: Loss from operations decreased by 45% in Q4 and 23% for the full year, indicating ongoing financial challenges despite improvements.
Operating Loss Analysis: The company is still operating at a loss, with an adjusted loss from operations of $47.6 million in Q4 and $199.6 million for the full year, reflecting significant financial strain.
Path to Profitability: Despite strong revenue growth, the company has not yet reached profitability, with expectations set for Q4 2025, indicating a prolonged path to financial stability.
R&D Expense Decline: R&D expenses declined by 36% in Q4 and 12% for the full year, suggesting potential cutbacks in research initiatives that could impact future product development.
Product Dependency Risks: The company is heavily reliant on the success of a few key products, such as VYVGART, which may pose risks if market conditions change or if competition increases.
2025 Revenue Guidance Outlook: The revenue guidance for 2025 is between $560 million to $590 million, which, while an increase, may not meet investor expectations for aggressive growth targets.
ZLAB FAQs
How does ZLAB typically perform around its earnings report dates?
Is Zai Lab Ltd (ZLAB) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ZLAB Earning Call Sentiment
Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript
ZLAB.O
-0.33%Positive
The earnings call revealed strong financial performance with a 66% increase in Q4 revenue and a 50% increase for the year, primarily driven by VYVGART's successful launch. The company is on track for profitability by Q4 2025, with a robust cash position supporting growth. Despite some uncertainties in clinical trials and market penetration challenges, optimistic guidance and growth prospects for other products like ZEJULA and NUZYRA contribute to a positive outlook. Given the market cap, a positive stock price movement of 2% to 8% is expected.
